Sitagliptin Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Sitagliptin Hydrochloride |
| DrugBank ID | DB01261 |
| Brand Names (EU) | Sitagliptin Accord |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.87% |
Approved Indication (EMA)
For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control: as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | opsismodysplasia | 98.87% | DL |
| 2 | diabetes mellitus (disease) | 98.68% | DL |
| 3 | classic stiff person syndrome | 98.66% | DL |
| 4 | focal stiff limb syndrome | 98.66% | DL |
| 5 | thiamine-responsive dysfunction syndrome | 98.57% | DL |
| 6 | drug-induced localized lipodystrophy | 97.99% | DL |
| 7 | pancreatic agenesis | 97.88% | DL |
| 8 | centrifugal lipodystrophy | 97.87% | DL |
| 9 | pressure-induced localized lipoatrophy | 97.81% | DL |
| 10 | idiopathic localized lipodystrophy | 97.66% | DL |
| 11 | autoimmune oophoritis | 87.99% | DL |
| 12 | type 1 diabetes mellitus | 86.45% | DL |
| 13 | cholangiocarcinoma, susceptibility to | 65.01% | DL |
| 14 | hemoglobin C-beta-thalassemia syndrome | 62.01% | DL |
| 15 | homozygous familial hypercholesterolemia | 60.51% | DL |
| 16 | mitral valve prolapse, myxomatous | 60.40% | DL |
| 17 | pancreas, dorsal, agenesis of | 58.41% | DL |
| 18 | familial chronic myelocytic leukemia-like syndrome | 58.22% | DL |
| 19 | woolly hair, autosomal recessive 3 | 58.09% | DL |
| 20 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 58.01% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.